search
new
antivir
proceed
unabatedli
previou
review
stori
antivir
drug
discoveri
review
variou
subject
person
review
hope
first
new
seri
address
hot
topic
area
antivir
research
past
year
signific
progress
made
requir
due
attent
compound
cover
still
preclin
stage
compound
success
complet
phase
ii
iii
clinic
trial
progress
approv
alreadi
approv
subject
review
instead
articl
base
compound
pipelin
offer
attract
perspect
futur
antivir
drug
sens
present
survey
littl
arbitrari
select
topic
depend
least
part
prejudic
number
factor
least
acquaint
subject
import
impetu
initi
review
base
icar
abstract
issu
antivir
research
vol
cover
present
icar
intern
confer
antivir
research
held
sofia
bulgaria
may
unfortun
could
attend
confer
guid
certain
devot
went
abstract
issu
spot
number
interest
lead
would
like
reflect
present
articl
nucleosid
analogu
target
hepat
c
viru
hcv
rna
polymeras
ii
cyclopropavir
treatment
human
cytomegaloviru
hcmv
infect
iii
treatment
herp
simplex
viru
type
type
viru
ebv
kaposi
herpesviru
kshv
infect
iv
cidofovir
treatment
broad
varieti
dna
viru
infect
v
favipiravir
treatment
influenza
viru
infect
variou
rna
viru
infect
vi
increas
number
compound
found
effect
arenavirus
vii
new
picornaviru
ie
rhinoviru
inhibitor
viii
natur
product
antivir
activ
aglycoristocetin
tricin
ix
mitogen
extracellular
kinas
mek
inhibitor
act
cellular
target
effect
influenza
virus
x
two
uniqu
set
compound
effect
virtual
envelop
dna
rna
taken
togeth
compound
x
cover
major
viral
pathogen
retrovirus
particularli
hsv
hcmv
hemorrhag
fever
influenza
human
immunodefici
viru
hiv
fdc
could
consid
first
nucleosid
analogu
fig
found
inhibit
hepat
c
viru
hcv
replicon
cell
cultur
inhibit
introduct
methyl
group
posit
fig
confer
similar
potenc
fdc
hcv
replicon
although
fig
demonstr
somewhat
lesser
activ
hcv
prodrug
ester
valopicitabin
fig
develop
later
drop
phase
ii
clinic
introduct
group
fig
significantli
increas
potenc
hcv
replicon
system
ie
effect
concentr
valu
nm
latter
two
compound
ester
prodrug
fig
longer
develop
inhibitor
hcv
accord
reddi
et
accord
reddi
et
fig
current
phase
iib
clinic
trial
ester
prodrug
fig
combin
studi
current
standard
care
soc
hcv
infect
ie
combin
pegyl
ribavirin
demonstr
efficaci
genotyp
patient
therefor
repres
first
direct
act
antivir
show
hcv
coverag
clinic
potent
inhibitor
hcv
replic
hcv
replicon
system
effici
diastereoselect
synthesi
see
wang
et
activ
rna
polymeras
level
must
phosphoryl
success
triphosph
final
activ
metabolit
act
chain
termin
rna
howev
addit
uridin
counterpart
fig
also
second
metabolit
also
potent
inhibitor
hsv
rna
deamin
occur
fig
inact
hcv
replicon
system
phosphoramid
prodrug
fig
activ
system
releas
phosphoryl
intracellularli
uridin
homolog
renam
anoth
phosphoramid
prodrug
fig
prepar
prove
inhibitor
hcv
replic
howev
lesser
activ
replicon
mutant
mutat
remain
fulli
suscept
insid
cell
convert
sens
consid
prodrug
fact
mixtur
two
diastereoisom
rp
diastereom
sp
diastereom
latter
activ
inhibitor
hcv
rna
replic
replicon
current
evalu
phase
ii
clinic
phosphoramid
prodrug
prepar
fig
prove
highli
activ
genotyp
hcv
rna
replic
replicon
system
genotyp
infecti
viru
product
hcv
replicon
harbor
r
acid
isopropyl
ester
activ
isom
mixtur
two
diastereoisom
recent
phosphat
prodrug
fig
describ
base
hcv
activ
replicon
rang
also
includ
activ
mutat
abil
produc
high
intracellular
level
vitro
vivo
synthet
access
singl
select
compound
current
phase
clinic
trial
support
continu
develop
clinic
candid
treatment
hcv
infect
methoxi
phosphorylamino
propano
guanosin
hcv
replicon
around
separ
diastereom
shown
similar
activ
replicon
assay
complet
investig
new
drug
ind
enabl
studi
progress
human
clinic
trial
treatment
chronic
hcv
cyclopropavir
fig
view
structur
relat
acyclovir
ganciclovir
penciclovir
acycl
side
chain
latter
replac
methylenecyclopropan
antivir
properti
known
sinc
decad
cyclopropavir
proven
effect
proven
particularli
effect
anim
model
cytomegaloviru
cmv
includ
scid
sever
combin
immunodefici
mous
model
addit
cyclopropavir
also
found
effect
vitro
human
herpesviru
type
like
hcmv
current
avail
drug
treatment
hcmv
infect
ganciclovir
cidofovir
foscarnet
valganciclovir
valin
ester
ganciclovir
esterif
ganciclovir
increas
oral
bioavail
previous
also
shown
acyclovir
valaciclovir
would
later
shown
valin
ester
valtorcitabin
valopicitabin
also
ester
cyclopropavir
valcyclopropavir
fig
mice
oral
bioavail
valcyclopropavir
hcmv
strain
cyclopropavir
compar
ganciclovir
cyclopropavir
display
tenfold
lower
also
case
mutat
affect
cyclopropavir
ganciclovir
suscept
fact
purifi
phosphoryl
cyclopropavir
monophosph
extens
phosphoryl
stereoselect
cyclopropavir
monophosph
convert
success
diphosph
triphosph
latter
activ
metabolit
interact
hcmv
dna
polymeras
singl
cellular
enzym
guanosin
monophosph
kinas
gmpk
monophosph
form
viral
encod
new
safe
drug
eagerli
await
fact
cyclopropavir
excel
activ
hcmv
combin
specif
phosphoryl
viral
enzym
would
seem
justifi
develop
compound
valin
ester
valcyclopropavir
eventu
phosphon
cyclic
phosphon
curiou
regard
phosphon
cyclic
phosphon
fig
equal
activ
hcmv
phosphon
cyclic
phosphon
activ
pseudosugar
rigidli
fix
northern
conform
hydroxymethyl
bicyclo
hexan
fig
first
synthes
marquez
et
al
found
exhibit
potent
antivir
activ
corrobor
subsequ
appear
phosphoryl
diphosph
thymidin
kinas
inhibit
viral
dna
polymeras
triphosph
kinas
would
prefer
substrat
adopt
sugar
conform
wherea
cellular
dna
polymeras
almost
exclus
incorpor
triphosph
lock
n
conform
notwithstand
presenc
higher
triphosph
level
fig
antivir
activ
vaccinia
viru
first
shown
carbocycl
thymidin
fig
found
highli
effect
orthopoxviru
infect
vivo
mice
although
lung
nasal
brain
viru
reduct
achiev
vaccinia
viru
infect
strain
nearli
extent
vaccinia
viru
lack
gene
encod
function
deoxyuridin
triphosphatas
dutpas
catalyz
convers
dutp
dump
continu
replic
well
vitro
vivo
prove
hypersensit
inhibitori
effect
activ
spectrum
activ
also
appar
inhibit
lytic
kshv
dna
synthesi
triphosph
metabolit
produc
cell
express
viral
encod
thymidin
recent
greener
enantioselect
synthesi
new
mct
distinct
name
fig
describ
substrat
thymidin
show
potent
activ
human
osteosarcoma
ho
cell
modifi
contain
express
thymidin
kinas
possibl
activ
may
mask
repres
interest
conform
therapeut
util
howev
remain
demonstr
present
therapeut
option
ebv
kshv
infect
infect
may
well
repres
uniqu
opportun
clinic
potenti
explor
hdp
prodrug
acycl
nucleosid
phosphon
cidofovir
cdv
repres
oral
version
cidofovir
reduc
nephro
activ
form
cidofovir
fig
explain
principl
possess
activ
spectrum
similar
cidofovir
thu
encompass
dna
virus
poxvirus
indic
could
given
oral
bioavail
safer
nephro
toxic
profil
replac
cidofovir
futur
therapeut
regimen
dissemin
central
nervou
system
cn
hsv
infect
firm
chimerix
cmx
appear
superior
oral
administ
eightfold
activ
molar
basi
intraperiton
administ
cidofovir
hcmv
infect
scidhu
exhibit
enhanc
antivir
activ
hcmv
hsv
replic
oral
treatment
effect
parenter
cdv
treatment
murin
cmv
long
await
oral
improv
outcom
cmv
infect
congenit
model
cmv
infect
pregnant
guinea
ether
lipid
ester
cidofovir
much
potent
cidofovir
adenoviru
replic
suppress
mortal
immunosuppress
hamster
power
model
evalu
efficaci
first
case
success
erad
dissemin
adenoviru
infect
recent
report
sever
immunosuppress
pediatr
stem
cell
transplant
line
earlier
observ
inhibitori
effect
cidofovir
murin
primat
cidofovir
shown
inhibit
polyomaviru
bk
replic
human
renal
tubular
either
lipid
ester
cidofor
shown
inhibit
polyomaviru
bk
replic
vitro
lower
concentr
prove
highli
effect
inhibit
polyomaviru
bk
replic
primari
human
renal
tubular
epitheli
point
potenti
treatment
bk
viru
nephropathi
seen
kidney
transplant
recipi
jc
polyomaviru
infect
human
oligodendrocyt
lead
develop
progress
multifoc
leukoencephalopathi
shown
suppress
polyomaviru
jc
human
fetal
brain
svg
cell
svg
cell
line
deriv
primari
human
brain
cell
transfect
simian
viru
express
antigen
cell
recent
shown
inhibit
polyomaviru
jc
replic
human
brain
case
progress
multifoc
leukoencephalopathi
accompani
idiopath
lymphocytopenia
respond
success
treatment
alkoxyalkyl
ester
cidofovir
includ
intens
pursu
inhibit
orthopoxviru
first
proven
activ
vitro
vaccinia
viru
vivo
activ
virus
efficaci
demonstr
lethal
mousepox
model
base
lethal
aerosol
ectromelia
viru
infect
ancr
mice
improv
model
evalu
antipoxviru
therapi
base
use
mice
infect
mousepox
ectromelia
viru
prove
efficaci
ancr
ectromelia
viru
infect
mice
serv
model
support
licensur
antiorthopoxviru
therapeut
base
anim
efficaci
rule
genet
similar
ectromelia
viru
variola
monkeypox
lethal
mousepox
model
complet
protect
mortal
achiev
administr
delay
late
day
singl
dose
mgkg
administ
day
postinfect
suffic
effect
mousepox
also
efficaci
treatment
monkeypox
viru
infect
highli
virul
express
ectromelia
viru
recombin
may
afford
highest
efficaci
combin
anoth
antivir
drug
postexposur
prophylact
efficaci
also
demonstr
rabbit
infect
rabbitpox
compar
cdv
would
advantag
could
administ
oral
wherea
cdv
need
administ
intraven
unlik
cdv
may
lead
furthermor
variou
addit
alkoxyalkyl
ester
cdv
describ
may
worth
explor
potenti
advantag
favipiravir
fig
current
clinic
trial
japan
phase
iii
unit
state
phase
ii
treatment
influenza
viru
infect
mention
buy
et
vitro
vivo
activ
first
report
furuta
et
compound
show
potent
inhibitori
activ
influenza
b
c
virus
activ
paramyxovirus
activ
whatsoev
dna
virus
structur
immedi
clear
mode
action
differ
ion
channel
inhibitor
amantadin
rimantadin
well
neuraminidas
inhibitor
zanamivir
oseltamivir
mechan
action
address
furuta
et
within
cell
would
convert
ribofuranosyl
monophosph
purin
adenin
hypoxanthineguanin
phosphoribosyl
transferas
two
phosphoryl
would
gener
rtp
activ
metabolit
latter
inde
activ
metabolit
also
shown
cell
infect
highli
pathogen
influenza
meanwhil
sidwel
et
shown
oral
administ
dosag
mgkg
twice
daili
prevent
death
due
lethal
avian
influenza
viru
infect
mice
vitro
favipiravir
prove
antivir
activ
influenza
viru
strain
resist
antivir
drug
vivo
synergist
effect
obtain
favipiravir
combin
oseltamivir
influenza
carboxamid
group
present
favipiravir
reminisc
carboxamid
present
ribavirin
carboxamid
group
also
present
two
compound
structur
relat
fig
compound
share
ribavirin
activ
variou
rna
virus
thu
show
activ
diseas
viru
fmdv
administ
food
could
power
tool
control
diseas
proven
efficaci
yellow
fever
viru
yfv
hamster
model
yfv
also
activ
bovin
viral
diarrhea
viru
bvdv
anoth
flaviviru
could
consid
surrog
viru
hepat
c
viru
hcv
also
efficaci
yfv
hamster
model
although
dose
requir
efficaci
hamster
higher
requir
efficaci
yet
improv
diseas
paramet
hamster
may
indic
potenti
util
treatment
yfv
infect
rodent
mice
hamster
oral
administ
also
effect
west
nile
viru
wnv
anoth
flaviviru
relat
yfv
whether
analogu
would
effect
two
mosquito
born
flavivirus
dengu
viru
japanes
enceph
viru
remain
intrigu
possibl
worth
explor
western
equin
enceph
viru
weev
alphaviru
belong
broad
famili
flavivirida
would
seem
respond
antivir
activ
spectrum
extend
arenavirus
junin
viru
junv
pichind
viru
tacarib
viru
machupoviru
macv
guanarito
viru
gtov
replic
cell
cultur
could
inhibit
previous
note
inhibitori
effect
influenza
viru
antiarenaviru
activ
could
revers
addit
purin
pyrimidin
also
prove
efficaci
pichind
viru
infect
hamster
even
treatment
begun
anim
fell
ill
day
anim
began
succumb
thu
treatment
late
stage
arenavir
hemorrhag
fever
could
consid
altern
option
ribavirin
would
seem
import
sever
arenaviru
infect
lassa
fever
human
besid
arenaviru
infect
bunyavirus
punta
toro
la
cross
rift
valley
fever
sandfli
fever
viru
also
proven
sensit
inhibit
vitro
punta
toro
viru
also
vivo
mice
hamster
hamster
infect
punta
toro
viru
efficaci
mice
bunyavirida
hantavirus
dobrava
mapor
found
sensit
inhibitori
effect
mapor
viru
phylogenet
similar
and
viru
princip
caus
hantaviru
cardiopulmonari
syndrom
hcp
argentina
would
seem
mandatori
explor
efficaci
suitabl
hantaviru
model
hamster
andor
mice
conclus
intrigu
new
antivir
compound
explor
clinic
potenti
preventiontherapi
influenza
viru
infect
also
broad
activ
spectrum
rna
strand
virus
target
action
rna
polymeras
rna
virus
relationship
pharmacodynam
rel
relat
structur
analogu
sinc
mccormick
pioneer
paper
effect
therapi
lassa
fever
ribavirin
ribavirin
remain
antivir
drug
avail
treatment
arenaviru
infect
inhibitori
effect
ribavirin
arenavirus
might
least
partial
attribut
lethal
recent
year
antiarenavir
drug
develop
receiv
increas
one
new
antiarenavir
drug
candid
favipiravir
see
preced
section
tacarib
arenaviru
infect
model
employ
explor
antivir
potenti
novel
aristeromycin
new
imidazo
thiazol
carbohydr
deriv
found
inhibit
replic
argentin
hemorrhag
fever
viru
small
interf
si
rna
target
conserv
rna
termini
lassa
fever
offer
therapeut
potenti
wherea
antimicrobi
cation
peptid
found
activ
junv
well
lassa
fever
viru
restrict
bone
marrow
stromal
antigen
also
call
tetherin
besid
inhibit
releas
also
inhibit
egress
tetherin
could
thu
consid
innat
immun
strategi
suppress
arenaviru
replic
lassa
fever
viral
nucleoprotein
np
endow
sever
function
ie
exoribonucleas
involv
suppress
interferon
induct
site
protect
cap
cap
snatch
may
serv
potenti
target
chemotherapeut
one
fascin
target
novel
antiarenaviru
strategi
arenaviru
envelop
glycoprotein
complex
gpc
process
cellular
site
proteas
strictli
requir
product
infecti
progeni
viru
small
molecul
fig
recent
report
potent
inhibitor
vitro
assay
correl
compound
potent
antivir
activ
lassa
fever
viru
cell
small
molecular
weight
inhibitor
target
arenavir
entri
particular
viral
glycoprotein
first
announc
chosen
drug
develop
fig
arenaviru
gp
synthes
singl
polypeptid
undergo
posttransl
process
yield
matur
virion
glycoprotein
involv
receptor
bind
wherea
similar
fusion
protein
envelop
virus
retrovirus
paramyxovirus
filovirus
seri
small
molecul
includ
fig
identifi
target
arenaviru
small
molecul
entri
inhibitor
includ
interact
envelop
gpc
arenavirus
stabil
complex
activ
membran
fusion
fig
inhibit
dissoci
subunit
gpc
thu
stabil
gpc
would
otherwis
initi
fusion
antivir
potenc
fig
lassa
viru
arenaviru
pseudotyp
within
rang
nm
sensit
dictat
segment
amino
acid
within
subunit
region
includ
region
ectodomain
transmembran
domain
envelop
small
molecul
arenaviru
inhibitor
compar
ribavirin
guinea
pig
model
lassa
viru
infect
found
increas
surviv
rate
control
ribavirin
remain
establish
compar
arenaviru
inhibitor
favipiravir
term
efficaci
safeti
whether
efficaci
extrapol
lassa
arenaviru
infect
junin
machupo
sabia
guanarito
although
picornavirus
encompass
number
import
human
pathogen
includ
enterovirus
polio
coxsacki
b
echo
rhinovirus
still
singl
antipicornaviru
agent
approv
clinic
use
yet
wealth
compound
shown
inhibit
picornavirus
includ
especi
coxsacki
b
viru
number
natur
product
see
section
promin
among
current
envisag
antipicornaviru
origin
winthrop
compound
disoxaril
deriv
engag
specif
bind
viral
capsid
pleconaril
fig
prototyp
class
shown
inhibit
replic
variou
demonstr
tent
efficaci
potenti
enteroviru
reject
us
fda
treatment
common
sever
trial
pleconaril
infant
enteroviru
adult
common
conduct
pevear
et
show
efficaci
pleconaril
reduc
durat
sever
common
cold
symptom
administ
within
hr
symptom
onset
relat
viru
suscept
pleconaril
de
palma
et
review
mention
phase
ii
trial
evalu
effect
pleconaril
nasal
spray
common
cold
symptom
asthma
exacerb
follow
rhinoviru
exposur
complet
result
trial
yet
divulg
pleconaril
meantim
found
shorten
cours
ill
compar
placebo
patient
enterovir
mening
benefit
appear
modest
adjust
confound
pleconaril
effect
viral
replic
common
variabl
immunodefici
cvid
patient
new
pleconaril
deriv
report
activ
coxsacki
b
meanwhil
new
benzimidazol
deriv
synthes
found
activ
coxsacki
small
interf
si
rna
shown
block
coxsacki
b
viru
synergist
activ
coxsacki
viru
obtain
sirna
combin
solubl
new
class
compound
structur
describ
recent
describ
inhibit
varieti
enterovirus
coxsacki
coxsacki
echoviru
low
micromolar
earlier
paper
date
demonstr
coxsacki
myocard
mice
inhibit
mycophenol
interferon
induc
ampligen
poli
poli
u
three
antipicornaviru
agent
current
clinic
develop
pleconaril
fig
pleconaril
develop
oral
formul
treatment
rhinoviru
infect
patient
chronic
lung
oral
phase
ii
trial
symptomat
human
rhinoviru
infect
asthmat
scrutini
treatment
polioviru
infect
valu
respect
human
rhinoviru
type
enteroviru
pleconaril
human
rhinoviru
type
polioviru
type
pleconaril
behav
capsid
binder
could
requir
combin
provid
addit
slightli
synergist
antivir
review
antivir
direct
human
rhinovirus
could
use
treat
common
cold
also
employ
therapeut
prophylact
prevent
asthma
chronic
obstruct
pulmonari
diseas
copd
exacerb
patient
natur
compound
primarili
origin
plant
receiv
increas
attent
antivir
potenti
typic
exampl
constitu
ardisia
chimensi
caffeoylquin
acid
schefflera
origin
southern
china
found
activ
particularli
coxsacki
viru
norsesquiterpenoid
isol
root
phyllanthu
emblica
show
activ
coxsacki
triterpenoid
isol
heptaphylla
fig
accredit
broader
activ
coxsacki
influenza
respiratori
syncyti
viru
rsv
fig
main
isoflavonoid
isol
astragalu
membranaceu
also
show
activ
coxsacki
viru
vitro
would
improv
surviv
rate
mice
infect
coxsacki
flavan
isol
leav
pithecellobium
clypearia
would
show
activ
array
virus
coxsacki
influenza
rsv
triterpenoid
mention
homoisoflavonoid
fig
show
activ
coxsacki
viru
echoviru
flavon
tricin
isol
bamboo
sasa
found
effect
hcmv
mean
stronger
antivir
activ
tricin
also
accredit
antiinfluenza
viru
increas
oral
bioavail
tricin
conjug
acid
prodrug
tricin
acid
show
excel
oral
bioavail
upon
oral
administr
isoflavon
genistein
fig
origin
isol
ferment
broth
pseudomona
initi
describ
protein
kinas
recent
genistein
shown
inhibit
arenaviru
put
inhibit
arenaviru
entri
occur
endocyt
genistein
found
increas
surviv
rate
hamster
infect
arenaviru
pirit
viru
surrog
model
hemorrhag
fever
caus
raoulic
acid
fig
princip
ingredi
raoulia
australi
shown
inhibit
picornavirus
rhinoviru
rhinoviru
coxsacki
coxsacki
enteroviru
valu
rang
lower
concentr
aforement
triterpenoid
flavan
show
antivir
howev
raoulic
acid
show
activ
influenza
terameprocol
methyl
deriv
nordihydroguaiaret
acid
phenol
antioxid
extract
creosot
bush
larrea
terameprocol
fig
found
inhibit
growth
poxvirus
cowpox
vaccinia
prevent
spread
viru
particl
cell
nigericin
also
known
antibiot
helexin
c
azalomycin
antibiot
polyetherin
also
shown
inhibit
poxviru
previous
report
inhibit
polioviru
influenza
viru
aglycoristocetin
deriv
cyclobutenedion
carri
hydrophob
chain
methylen
bi
phenylen
fig
inhibit
influenza
b
viru
infect
probabl
interfer
viral
entri
type
compound
deriv
glycopeptid
antibiot
previous
shown
inhibit
replic
coronavirus
inhibitori
effect
also
attribut
interfer
viru
brassinosteroid
fig
repres
natur
occur
polyhydroxi
steroid
plant
hormon
modul
growth
differenti
plant
cell
antivir
activ
well
brassinosteroid
particularli
activ
arenavirus
tacarib
pichind
biyouyanagin
b
origin
obtain
hypericum
chinens
shown
activ
compound
possess
antiarenaviru
properti
recent
obtain
total
synthesi
origin
assign
structur
revis
fig
conclus
wealth
natur
product
report
possess
antivir
properti
major
case
chemic
structur
well
identifi
full
antivir
activ
spectrum
compound
still
need
evalu
mode
action
elucid
importantli
therapeut
valu
delin
fig
prototyp
mek
proteinextracellular
kinas
inhibitor
act
tier
serinethreonin
kinas
regul
kinas
erk
signal
pathway
abl
suppress
propag
pandem
influenza
viru
highli
pathogen
avian
influenza
viru
vitro
among
mek
inhibitor
pd
pd
fig
use
clinic
trial
also
inhibitori
influenza
viru
infect
mek
inhibitor
reduc
viru
titer
vitro
vivo
also
reduc
proinflammatori
cytokin
mek
inhibitor
also
shown
suppress
influenza
b
viru
importantli
date
happen
without
emerg
resist
viru
variant
demonstr
influenza
virus
easili
adapt
interfer
cellular
function
influenza
viru
infect
requir
induct
varieti
cytokin
includ
regul
transcript
factor
activ
famili
nk
kinas
differ
protein
kinas
pathway
may
ultim
lead
rant
product
influenza
human
bronchial
epitheli
rafmekerk
cascad
prototyp
protein
map
kinas
cascad
inhibit
result
nuclear
retent
viral
ribonucleoprotein
complex
rnp
concomit
inhibit
viru
product
signal
mitogen
cascad
seem
essenti
influenza
viru
raf
mek
erk
pathway
play
import
role
replic
influenza
b
viru
also
replic
coxsacki
viru
mek
inhibitor
therefor
impair
propag
virus
specif
shown
rafmekerk
signal
cascad
activ
upon
infect
borna
diseas
viru
bdv
noncytolyt
highli
neurotrop
rna
viru
known
member
bornavirida
mononegaviral
mek
inhibitor
found
block
spread
bdv
cultur
pathogenesi
hemorrhag
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
poorli
understood
hemorrhag
may
relat
induct
plasminogen
activ
inhibitor
type
via
activ
mekerk
pathway
mek
inhibitor
almost
complet
suppress
may
therefor
assum
suppress
hemorrhag
dhfdss
mekerk
pathway
also
associ
map
kinas
mapk
may
contribut
visna
process
lead
neurodegen
patholog
treatment
visna
cell
pd
fig
sinc
long
recogn
specif
inhibitor
abolish
visna
viru
attest
potenti
pd
prevent
neuropatholog
visna
viru
replic
hcmv
depend
number
protein
kinas
pathway
sorafenib
multitarget
tyrosin
kinas
inhibitor
regist
anticanc
treatment
bayer
onyx
pharmaceut
mapk
signal
pathway
sorafenib
may
also
interfer
replic
imatinib
may
suppress
hcmv
replic
inactiv
growth
receptor
pdgfr
critic
receptor
requir
hcmv
variou
protein
kinas
inhibitor
contain
quinazolin
moieti
gefitinib
astrazeneca
teva
exert
activ
vitro
vivo
gefitinib
also
inhibit
hcmv
kinas
furthermor
hcmv
replic
depend
mekerk
pathway
could
therefor
suppress
mek
inhibitor
pd
conclus
mek
inhibitor
may
exhibit
activ
multitud
virus
includ
influenza
herp
simplex
hiv
retrovirus
dengu
corona
hcmv
although
antivir
effect
could
consid
highli
specif
advantag
mek
inhibitor
view
action
target
cellular
process
unlik
lead
rapid
emerg
drug
resist
februari
issu
proc
natl
acad
sci
usa
appear
paper
antivir
agent
target
entri
envelop
follow
octob
issu
journal
remark
similar
antivir
activ
structur
unrel
inhibitor
rhodanin
deriv
rigid
amphipath
fusion
inhibitor
rafi
deriv
fig
possess
rigid
planar
hydrophob
moieti
hydrophob
moieti
would
intercal
lipid
bilay
viral
envelop
therebi
affect
fusion
process
principl
activ
envelop
virus
two
import
human
pathogen
hcv
hsv
activ
demonstr
sever
other
ie
yellow
fever
dengu
japanes
enceph
fact
compound
compar
side
side
spectrum
activ
admittedli
easili
lead
drug
resist
develop
issu
address
vivo
activ
select
biodistribut
drug
formul
pharmacodynam
therapeut
valu
could
assess
herald
new
approach
strategi
combat
envelop
viru
infect
question
rais
whether
druggabl
well
